Favipiravir Dosing for Influenza
Favipiravir is not currently approved or recommended for routine influenza treatment in the United States or by major international guidelines; oseltamivir, zanamivir, baloxavir, or peramivir remain the standard-of-care antivirals for influenza.
Current Regulatory Status
The provided evidence contains no FDA-approved dosing for favipiravir for influenza in the United States. The drug references 1 discuss famciclovir (an entirely different antiviral for herpes viruses), not favipiravir. Major U.S. and international pediatric influenza guidelines from 2010-2021 2, 3, 4, 5, 4 exclusively recommend oseltamivir, zanamivir, peramivir, and baloxavir—favipiravir is conspicuously absent from all guideline recommendations.
Japan-Approved Dosing (For Reference Only)
Favipiravir is approved only in Japan for influenza resistant to other antivirals. The Japan-licensed regimen is:
- Loading dose: 1600 mg orally twice daily on Day 1
- Maintenance dose: 600 mg orally twice daily on Days 2-5
Research Dosing Regimens Studied
Higher doses have been investigated in clinical trials:
Uncomplicated Influenza (Phase 3 Trials)
- Loading: 1800 mg twice daily on Day 1
- Maintenance: 800 mg twice daily on Days 2-5
This regimen showed inconsistent efficacy—one trial demonstrated 14.4-hour reduction in illness duration (p=0.004), while a second trial showed no significant benefit 7. Importantly, 41-43% of patients failed to achieve therapeutic plasma concentrations (Cmin ≥20 µg/mL) with this dosing, particularly those weighing >80 kg 8.
Severe/Hospitalized Influenza
Even the 1800/800 mg regimen proved inadequate for critically ill patients. Pharmacokinetic modeling suggests ≥3600 mg loading dose followed by ≥2600 mg twice daily maintenance may be required to achieve target concentrations in severe disease 9.
Critical Limitations
Pharmacokinetic variability is extreme: Wide interindividual differences in favipiravir metabolism mean standard dosing fails to achieve therapeutic levels in a substantial proportion of patients, especially those >80 kg 8. Higher plasma concentrations (Cmin >20 µg/mL) correlate with greater viral load reduction and faster symptom resolution 8.
Efficacy concerns: While favipiravir demonstrates antiviral activity (reduced viral titers and RNA load), clinical benefit for symptom resolution is inconsistent 7. Recent comparative data show baloxavir has superior viral clearance (86% acceleration vs. no treatment), followed by favipiravir (66%), then oseltamivir (49%) 10.
Safety profile: Generally well-tolerated with asymptomatic hyperuricemia as the primary concern. Gastrointestinal effects and transaminase elevations occur 6. Contraindicated in pregnancy due to teratogenic potential in animal studies 6.
Clinical Recommendation
For influenza treatment in adults and children ≥12 years, use guideline-recommended antivirals:
- Oseltamivir: 75 mg twice daily for 5 days (adults); weight-based dosing for children 3, 5
- Baloxavir: Single dose (40 mg for 40-80 kg; 80 mg for >80 kg) 3, 5
- Zanamivir: 10 mg (two 5-mg inhalations) twice daily for 5 days 3, 5
- Peramivir: Single 600 mg IV infusion 3, 5
Favipiravir should only be considered in research settings or when all approved antivirals are contraindicated, unavailable, or the virus demonstrates pan-resistance—and even then, only with therapeutic drug monitoring if available given the high rate of subtherapeutic dosing with standard regimens.